Home >Technologies Available >Technologies available for licensing

Alkyne-containing SARS-CoV-2 main protease inhibitors

Image from Licence Details: Alkyne-containing SARS-CoV-2 main protease inhibitors

Applications: Antivirals, viral inhibitors, protease inhibitors, small molecule drugs, SARS-CoV-2, COVID-19 treatment

Features Benefits
  • Novel small-molecules using alkyne groups to inhibit the SARS-CoV-2 main protease.
  • New antiviral for the treatment of COVID-19.
  • Selective irreversible covalent reaction of viral main proteases and other nucleophilic cysteine proteases.
  • Alkynes are substantially less reactive towards reaction with nucleophiles than most other functional groups, enhancing selectivity for target inhibition versus off target inhibition.
  • Alkyne bearing small-molecules less likely to interfere with host proteins.
  • Highly desired from a drug safety perspective.
  • Alkynes can be functionalised at their terminal position.
  • Optimises inhibition and selectivity, including with respect to drug-resistant Mpro variants, as well as their pharmacodynamic and pharmacokinetic properties.
  • Demonstrated inhibition of other related viral, bacterial, and human proteases.
 Potential for treatment of other viral infections, such as with middle eastern

  • respiratory syndrome (MERS)

Patented and available for: 

  • Licensing
  • Co-development
  • Consulting
Request more information
about this technology

Back to Technologies Available

Sparks Background Image

Ready to get in touch?

Contact Us
Sparks Background Image
© Oxford University Innovation